74 results about "Uremia" patented technology

The invention discloses a digital full-period monitoring and evaluating system for the internal fistula function of a uremia patient, and relates to the technical field of medical monitoring. By integrating a multi-mode sensor, intelligent data processing and cloud analysis technologies, comprehensive, accurate and real-time monitoring of the internal fistula function is realized. The system comprises a data acquisition unit, a data transmission unit, an intelligent processing terminal, a cloud server, a user interaction unit and a distributed storage unit, and can measure multi-dimensional physiological parameters such as blood flow velocity, blood flow volume and blood flow pressure and obtain the endovascular microstructure and elastic characteristics. And the cloud server executes multi-modal data fusion analysis, generates an early warning signal, and triggers alarms of different levels through a hierarchical early warning strategy. According to the system, the precision and comprehensiveness of internal fistula function monitoring are improved, the complication risk is reduced, and powerful technical support is provided for dialysis treatment of uremia patients.

The invention provides a high-sensitivity ammonia gas sensor for early chronic kidney disease diagnosis and uremia dialysis curative effect monitoring, and relates to the field of exhaled gas analysis of diseases. The preparation method of the gas sensor comprises the following steps: S1, preparing I n2O3 nanofibers by an electrostatic spinning method; s2, the collected eggshell membranes are treated and cleaned so as to be used for a flexible substrate; and S3, growing an aniline monomer and the In2O3 nanofibers on the surface of the eggshell membrane in an in-situ chemical oxidation polymerization manner to prepare the polyaniline composite In2O3 nanofiber flexible film based on the eggshell membrane as the substrate. According to the method, the concentration difference of NH3 and creatinine in exhaled gas of a patient and a healthy person is analyzed, painless early diagnosis of the chronic kidney disease is achieved, the dialysis process is monitored painlessly and the curative effect is evaluated by analyzing the change of the concentration of NH3 in exhaled gas of a uremia patient in the dialysis process, and meanwhile the result is obtained through clinical tests. The response value of the sensor to exhaled gas has a good linear relationship with clinical indexes of creatinine and blood urea nitrogen representing the content of in-vivo metabolic nitrogen waste.

Described herein are bacterial compositions of modified probiotic bacteria having tolerance to one or more uremic toxins. Compositions of the disclosure can be used in the treatment of subjects having a condition or who are at risk of developing a condition associated with uremic toxin build up. Also provided herein are methods of preparing bacterial compositions of the disclosure.

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting a complement component C3 (C3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica (NMO), multifocal motor neuropathy (MMN), myasthenia gravis (MG), C3 glomerulonephritis, or systemic lupus erythmatosis.

To provide a jelly composition containing spherical adsorptive carbon for improving uremic symptoms and delaying initiation of dialysis of chronic renal failure patients, which has more improved medication compliance than existing therapeutic agents.SOLUTION: The jelly composition contains spherical adsorptive carbon as an active ingredient, a gelling agent, a thickener, and spherical adsorptive carbon containing distilled water.SELECTED DRAWING: Figure 2

The present disclosure relates to a composition for use in preventing and / or treating renal failure, such as uremia, in a subject. Said composition is a composition for oral consumption and comprises i) an extract of Rhodiola rosea root, ii) L-arginine, iii) L-citrulline; and iv) an extract of beet root. Said composition is also useful for preventing or reducing a gain of body weight, or for reducing body weight, in a subject in need thereof.

The invention discloses a marker for diagnosing intestinal epithelial barrier injury induced by uremic toxin and application of the marker, and belongs to the technical field of biomedicine. Human colon cancer cells (Caco-2) are adopted to establish intestinal epithelial injury models under different urea treatment conditions, and the optimal concentration and time are screened through CCK-8 and immune blot. According to the present invention, RT-qPCR is adopted to detect the expression of lncRNANEAT1 and miR-122-5p, Westernblot and an immunofluorescence method are adopted to detect the expression of tight junction proteins Occludin, ZO-1 and Claudin-1, fluorescein sodium is adopted to detect the cell para-permeability of an intestinal epithelial injury model, and the combination of miR-122-5p with lncRNANEAT1 and Occludin is detected through bioinformatics analysis and dual-luciferase reporter gene analysis; the result shows that the lncRNANEAT1 can be used for protecting intestinal epithelial barrier injury induced by uremia toxin by regulating the miR-122-5p / Occludin axis. The discovery reveals an action mechanism of the lncRNANEAT1 in uremia toxin induced intestinal epithelial barrier injury, and provides a new thought and method for reducing complications of uremia patients and improving life quality.

This invention relates to a dialysis apparatus which ultra-filters blood and to a related method of ultra-filtering blood ex-vivo.More preferably the invention relates to haemodiafiltration using protein-losing membranes and a secondary ultrafiltration and partial re-infusion of haemodiafiltrate for increasing extraction of middle molecules and protein bound uraemic toxins and reducing albumin loss.

The application belongs to the technical field of adsorbents, and provides a composite adsorbent material for uremia and a preparation method thereof, and the preparation steps are as follows: S1. Acrylamide, N,N'-methylenebisacrylamide, glycerol and deionized water are mixed, stirred, sodium alginate is added, stirred and dissolved, ammonium persulfate, calcium sulfate and tetramethylethylenediamine are sequentially added, stirred, ultrasonically treated, and heated and reacted to obtain a sodium alginate derivative; S2. The sodium alginate derivative and deionized water are mixed, modified high-density polyethylene is added, stirred, and soaked in a CaCl2 solution for crosslinking to obtain a sodium alginate composite material; S3. CeO2 / MoS2 functional material, sodium alginate and deionized water are mixed, the sodium alginate composite material is added and stirred, shaped, soaked in a CaCl2 solution for crosslinking, washed, and dried to obtain the composite adsorbent material. The composite adsorbent material has a high adsorption rate and high adsorption capacity for uremia toxins, and has good biocompatibility and hemocompatibility.

Compositions and methods for detecting genetic structural variations (SVs) in a gene of interest, involved in disease pathologies commonly found in large Mendelian genomics programs; or for genetic mapping of mobile transposable elements, involved in genetic disease, cancer, and aging are disclosed. The methods include: (i) contacting a sample comprising genomic DNA with a DNA endonuclease for an effective amount of time to cleave the genomic DNA into fragments, the genomic DNA has not been crosslinked, (ii) subjecting the fragments obtained from step (b) to a DNA ligase to obtain circularized DNA, (iii) subjecting the circularized DNA to inverse PCR amplification comprising inverse primers, wherein the inverse primers are designed to align with anticipated wild-type sequences, adjacent to a suspected mutation locus in a gene, and (iv) sequencing the amplified product. Exemplary conditions include Bardet-Biedl syndrome; Severe upper and lower limb defects; Retinitis pigmentosa; Syndromic microcephaly; Spastic paraplegia; and atypical hemolytic uremic syndrome.

The application discloses a high-loading MXene-encapsulated magnetic porous microcapsule for adsorption and a preparation method and application thereof, and belongs to the field of biomedical materials, and the preparation method comprises the following steps: in step one, a hydrogel precursor solution doped with magnetic nanoparticles is used as an external phase, and a MXene dispersion liquid is used as an inner phase, and a microfluidic coaxial electrospraying device is used to generate monodisperse core-shell droplets with uniform sizes; in step two, the monodisperse core-shell droplets prepared in step one are subjected to freezing pretreatment, and then are crosslinked with divalent metal ions, so that double gelation of the core layer and the shell layer is triggered, and hydrogel microspheres with a core-shell structure are obtained; and in step three, the hydrogel microspheres with the core-shell structure obtained in step two are subjected to freeze drying, and high-loading MXene-encapsulated magnetic porous microcapsules are obtained. The application has excellent blood compatibility and high adsorption capacity, and is outstanding in removing uremic toxins including creatinine, urea and uric acid, and is a kind of adsorbent which is both efficient and safe.

The invention discloses a uremia clearing liquid preparation and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. The uremia clearing liquid preparation is prepared from the following raw materials: rheum officinale, astragalus membranaceus, white mulberry root-bark, radix sophorae flavescentis, codonopsis pilosula, bighead atractylodes rhizome, poria cocos, radix polygoni multiflori preparata, radix paeoniae alba, salvia miltiorrhiza, ligusticum wallichii, chrysanthemum, ginger processed pinellia, plantain herb, radix bupleuri, liquorice, a disodium hydrogen phosphate-citric acid buffer solution, beta-cyclodextrin, tween-80, xanthan gum, stevioside and water. By improving the preparation process and providing a new auxiliary material system, the stability of the oral liquid preparation is improved, the transfer rate of effective components is increased, the flavor is improved, and the palatability is improved.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

The invention provides a preparation process and a use method of a medicinal and edible substance composition. The medicine overcomes the defects that rejection reaction is insufficient when cancer is treated by a stem cell transplantation method and organ lesions cannot be treated simultaneously when cancer is treated by an immune cell method and a vaccine cell method; the oral liquid comprises the following raw materials in parts by weight: 0.1-3.0 parts of cordyceps militaris, 0.1-3.0 parts of fermented cordyceps sinensis powder, 1.0-3.5 parts of pseudo-ginseng, 1.0-2.5 parts of American ginseng, 1.0-1.5 parts of salvia miltiorrhiza powder or ligusticum wallichii, 1.0-3.0 parts of high-quality gastrodia elata and medicinal pure honey which is 0.9-1.3 times of the total weight of the medicinal materials. The preparation method comprises the following steps: mixing prescription raw materials, crushing, adding honey, and preparing honeyed boluses or beverages. The medicine disclosed by the invention is safe, can treat cancers, diabetes mellitus, heart diseases, liver diseases, nephropathy, uremia or entanglement of a plurality of diseases with high curative effect, and enables patients to be young; according to the invention, messy code genes of a patient can be normally edited while the disease is treated.

The present invention relates to the field of antibody technology, and specifically to a method for preparing and applying a recombinant monoclonal antibody against rT3. The present invention utilizes phage display technology to screen and obtain the rT3 recombinant rabbit monoclonal antibody of the present invention, wherein the heavy chain variable region thereof has the amino acid sequence shown in SEQ ID NO:1; and the light chain variable region thereof has the amino acid sequence shown in SEQ ID NO:2. The monoclonal antibody has strong specificity and high detection sensitivity, and solves the problem of low rT3 content in samples and high detection difficulty. It has been identified that repeated multiple detections using the monoclonal antibody have good stability and high accuracy. The antibody is used for the detection of rT3 content in serum, and combined with other thyroid index tests and clinical manifestations, it can diagnose hyperthyroidism and hypothyroidism, and is also clinically significant in the detection of diabetes, lung infection, myocardial infarction, cirrhosis, uremia, and some cancers.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronic kidney failure.

The invention provides a marker polypeptide composition for detecting uremia and a mass spectrum model for evaluating the curative effect of uremia. Wherein the marker polypeptide composition is mainly carbamoyl hemoglobin of alpha / beta globin, and comprises eight marker polypeptides with the following mass-to-charge ratios: 7564 m / z, 7585 m / z, 7934 m / z, 7956 m / z, 8476 m / z, 15127 m / z, 15170 m / z, 15868 m / z, 15911 m / z and 16952 m / z. The marker polypeptide composition disclosed by the invention can be used for detecting uremia. The detection method provided by the invention is simple, easy to operate and high in accuracy, and provides a new method and idea for uremia detection.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronicap kidney failure.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The application discloses a quantitative-discriminative integrated uremia intelligent detection system, and relates to the field of medical spectrum analysis.The system comprises a spectrum collection module, which is used for collecting near-infrared transmission spectrum data of a serum sample to be measured; and a double-model detection module, which is used for determining urea concentration and a uremia state of the serum sample to be measured by using a pre-constructed urea concentration quantitative regression model and a uremia state discriminative classification model respectively according to the near-infrared transmission spectrum data.The application realizes accurate determination of urea concentration and rapid automatic identification of uremia, and has significant advantages in reducing cost, simplifying process and improving diagnosis efficiency.

The present invention relates to the field of biomedicine technology, and proposes a heparin-capturing uremic toxin adsorbent and a preparation method thereof. The raw materials of the adsorbent include styrene, acrylic acid, and divinylbenzene. Through the above technical solution, using polystyrene as the basic skeleton, by introducing polar monomers into the main structure, and activating the introduction of active groups such as hydroxyl and chloromethyl groups on the skeleton surface, a heparin-capturing adsorbent is prepared that can be rapidly cross-linked with heparin surface active groups through physical and chemical reactions to form an anti-coagulant surface. This solves the problem in the prior art that uremic toxin adsorbents can cause coagulation complications when used clinically.

The present invention provides a traditional Chinese medicine composition for treating chronic kidney disease, which is prepared from the following raw materials in the following weight ratios: 4-6 parts of cimicifuga, 24-36 parts of rhubarb, 8-12 parts of polygonum cuspidatum, 12-18 parts of scutellaria baicalensis, 8-12 parts of artemisia capillaris, 4-6 parts of wax gourd peel, 4-6 parts of motherwort, 4-6 parts of leech, 4-6 parts of earthworm, 4-6 parts of safflower, and 4-6 parts of millettia reticulata. The present invention also provides a preparation method and use of the traditional Chinese medicine composition. The action site of the drug of the present invention focuses on the intestine, and enema directly acts on the colon, which can accelerate intestinal kinetics, improve intestinal barrier function, reduce the production and absorption of enterogenous uremic toxins such as indoxyl sulfate, reduce renal fibrosis, relieve renal fibrosis, and has a significant correlation with regulating TLR4 / MyD88 / NF-κB inflammatory response and systemic inflammation, providing a new option for the treatment of chronic kidney disease.

There is provided a compound comprising a nucleophile for use in topical formulation for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject.

The described technology can include methods of treating a population of red blood cells (RBCs) in an individual, particularly a chronic kidney disease (CKD) patient with renal anemia, by reducing the amount of a Piezo1 chemical agonist in the patient's blood. In one embodiment, a method of treating a patient with renal anemia can include increasing RBC lifespan of a population of RBCs in the patient by reducing Piezo1 channel activation duration of at least a portion of the population of RBCs by reducing the amount of a target uremic compound in the patient's blood, the target uremic compound having a form that prolongs Piezo1 channel activation duration, wherein the amount of the target uremic compound can be reduced by selectively removing at least a portion of the target uremic compound from the patient's blood. Other embodiments are also described.

The ganoderma lucidum and mesona chinensis preparation is prepared from 10-100 g of ganoderma lucidum, 10-100 g of mesona chinensis (mesona chinensis), 10-100 g of rhizoma polygonati, 10-100 g of astragalus membranaceus, 10-100 g of dandelion, 10-100 g of herba cepbalanoplosis segeti, 10-100 g of fructus gardeniae, 10-100 g of honeysuckle, 10-100 g of pilea cavaleriei, 10-100 g of centipede, 10-100 g of cudrania cochinchinensis, 4-40 g of embroidery needle, 4-40 g of bitter The preparation can clear away heat and toxic materials, induce diuresis to alleviate edema, improve the immunity of a human body, effectively reduce serum creatinine, uric acid, blood pressure and blood sugar, improve the immunity of the human body, improve the immunity of the human body, reduce the toxic and side effects of the human body, reduce the toxic and side effects of the human body, reduce the toxic and side effects of the human body, and reduce the toxic and side effects of the human body. The traditional Chinese medicine composition has good treatment effects on uremia, nephritis, renal cyst, kidney stone, hepatitis B, cirrhosis, liver ascites, insomnia, asthma, pharyngitis, cough, cancerous diseases and cardia-cerebrovascular diseases.

The present invention provides a double-layer hollow fiber membrane for enclosing a hollow space through which blood flows and transporting uremic toxins and waste products from the blood to the outside, and a method for manufacturing the same. The double-layer hollow fiber membrane includes a first layer having first pores and a second layer having second pores. The first pores of the first layer and the second pores of the second layer are connected to each other, and the second pores are open pores connected to the outside. The double-layer hollow fiber membrane can remove uremic toxins with molecular sizes from blood while minimizing the loss of blood components and essential proteins due to the pores increasing in size from the first pores to the second pores.

The invention discloses resin with super-strong adsorption performance as well as a preparation method and application thereof. Macroporous adsorption resin is prepared from a polyvinyl cross-linking agent and a pore-foaming agent, and then a polymer is grafted through residual hanging double bonds. The macroporous adsorption resin prepared by using the method has a huge specific surface area and abundant pore channels, and has super-strong adsorption performance on macromolecular toxins such as parathyroid hormone and beta2-microglobulin in the body of a uremia patient, and in addition, hydroxyethyl polymethacrylate is grafted on the surface of the resin, so that the hemolysis rate is reduced, and the blood compatibility is improved.

The present invention discloses a functionalized nanofiber hemodialysis membrane and a preparation method, application and supporting equipment. The preparation method comprises: S1: preparation of a nanofiber hemodialysis membrane precursor; S2: preparation of a nanofiber membrane loaded with crystals; S3: preparation of a high-efficiency functionalized nanofiber hemodialysis membrane; in addition, the present invention also provides the application of the nanofiber hemodialysis membrane in a hemodialyzer and a hemodialysis machine. The high-efficiency functionalized nanofiber membrane prepared by the present invention has multiple functions such as adsorption, anti-oxidation, anti-inflammatory, anti-coagulation and antibacterial, effectively improves the ability to remove uremic toxins, can quickly remove uremic toxins in the patient's body while reducing the patient's complications. This functionalized nanofiber membrane is simple to prepare, and the raw materials are easily available, and has broad prospects in the field of hemodialysis materials. In addition, the designed nanofiber hemodialyzer and portable hemodialysis machine are simple to operate and lightweight, which is convenient for patients to carry and operate independently.